The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study to evaluate the efficacy and safety of combination therapy of durvalumab (MEDI4736) and amrubicin in patients with recurrent small cell lung cancer (SCLC): Aphrodite trial, in progress.
 
Yuka Kato
Honoraria - AstraZeneca/Hong Kong; Chugai Pharma
 
Kadoaki Ohashi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa Kirin; Lilly O.; MSD; Nippon Kayaku; Novartis
Research Funding - AstraZeneca/MedImmune; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Lilly O.
 
Toshiyuki Kozuki
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Kyowa-Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Shoichi Kuyama
No Relationships to Disclose
 
Kakuhiro Yamaguchi
No Relationships to Disclose
 
Toshihide Yokoyama
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Meyers-Squibb/Statistical Horizons (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Janssen (Inst); MSD K.K (Inst); PAREXEL (Inst); Takeda (Inst)
 
Hideki Uno
Stock and Other Ownership Interests - Takeda
 
Michihiro Yoshida
Stock and Other Ownership Interests - Takeda
 
Noboru Hattori
Honoraria - AstraZeneca; Boehringer Ingelheim
Research Funding - Lilly Japan (Inst); Taiho Oncology (Inst)
 
Katsuyuki Hotta
Honoraria - AZD; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly O.; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical
Research Funding - Abbvie; AZD; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD
 
Katsuyuki Kiura
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Lilly Japan; Merck; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo Pharmaceutical; Nippon Kayaku; Nipro Corporation
Research Funding - Boehringer Ingelheim; Chugai Pharma; Kyorin; Merck; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda; Teijin Pharma